Treace Medical Concepts, Inc. (TMCI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Treace Medical Concepts Q1 Earnings Call Highlights
Treace Medical Concepts NASDAQ: TMCI reaffirmed its full-year 2026 revenue outlook after reporting a first-quarter revenue decline, as management said new product adoption is helping drive procedure volume momentum despite pricing and mix headwinds.
Treace Medical Concepts, Inc. (TMCI) Q1 2026 Earnings Call Transcript
Treace Medical Concepts, Inc. (TMCI) Q1 2026 Earnings Call Transcript
Treace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue Estimates
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.25 per share a year ago.
Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript
Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript
Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Treace Medical Concepts, Inc. (TMCI) Q3 2025 Earnings Call Transcript
Treace Medical Concepts, Inc. ( TMCI ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Trip Taylor John Treace - Founder, Chairman & CEO Mark Hair - Chief Financial Officer Conference Call Participants Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Marie Thibault - BTIG, LLC, Research Division Jayna Renee Francis - UBS Investment Bank, Research Division Presentation Trip Taylor Good afternoon, everyone, and welcome to our third quarter 2025 earnings conference call. Participating from the company today will be John Treace, Chief Executive Officer; and Mark Hair, Chief Financial Officer.
Treace Medical Concepts (TMCI) Reports Q3 Loss, Beats Revenue Estimates
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.25 per share a year ago.
Treace Medical Concepts, Inc. (TMCI) Q2 2025 Earnings Call Transcript
Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants John T. Treace - Founder, Chairman & CEO Mark L.
Treace Medical Concepts (TMCI) Reports Q2 Loss, Beats Revenue Estimates
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.34 per share a year ago.
Wall Street Analysts See a 41.11% Upside in Treace Medical Concepts (TMCI): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Treace Medical Concepts (TMCI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Treace Medical Concepts, Inc. (TMCI) Q1 2025 Earnings Call Transcript
Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan Felipe Lamar - Truist Jayna Francis - UBS Operator Good day and thank you for standing by. Welcome to the Treace Medical Concepts First Quarter 2025 Earnings Conference Call.
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago.
